Table 2.
Incidences of hematological toxicity
| Age groups, years |
Overall p value | ||||
|---|---|---|---|---|---|
| < 60 | 60–64 | > 64 | Total | ||
| Neutropenia grade 3+4* | |||||
| n | 1,243 | 362 | 278 | 1,883 | |
| Treatment, % | |||||
| TAC | 37.5 | 56.7 | 55.2 | 43.0 | < 0.001 |
| Canadian FE120C | 67.0 | 62.6 | 76.5 | 67.7 | 0.127 |
| A(E)C-[T/P] | 52.8 | 52.0 | 65.5 | 54.2 | 0.012 |
| ddAT | 43.5 | 47.4 | 43.6 | 44.2 | 0.815 |
| ddE-ddP | 29.7 | 36.7 | 33.3 | 31.1 | 0.599 |
| Febrile neutropenia grade 3+4* | |||||
| n | 172 | 43 | 30 | 245 | |
| Treatment, % | |||||
| TAC | 9.3 | 11.3 | 14.3 | 10.0 | 0.088 |
| Canadian FE120C | 2.5 | 4.7 | 2.4 | 2.9 | 0.498 |
| A(E)C-[T/P] | 1.0 | 0.5 | 1.4 | 1.0 | 0.686 |
| ddAT | 4.5 | 5.1 | 5.1 | 4.7 | 0.960 |
| ddE-ddP | 0.0 | 6.4 | 0.0 | 0.9 | < 0.001 |
F = 5-fluouracil
A: adriamycin
E = epirubicin
C = cyclophosphamide
T = docetaxel
P = paclitaxel
dd = dose dense.
*
According to the National Cancer Institute Common Toxicity Criteria.